Notice
본문 바로가기
메인메뉴
Company
About Qurient
History
Management
Contact Us
Business Philosophy
Pipeline
Pipeline
Adrixetinib (Q702)
Q901
Q301
Telacebec (Q203)
5-Lipoxygenase Inhibitor
Clinical Trials
Clinical Trials
IR / PR
Notice
Press Release
Qurient in the news
Financial
Disclosure
Blog
WEBTOON
WEBTOON
Company
Pipeline
Clinical Trials
IR / PR
WEBTOON
Notice
Press Release
Qurient in the news
Financial
Disclosure
Blog
Notice
[CEO LETTER] 주주 여러분께
페이지 정보
Author
QURIENT
Date
2017-07-03 08:57
Views
19,118
본문
Prev
Next
List
information for download file
* Name
Company
Phone
* Business e-mail
Comment
Request Download
팝업 닫기